Dr. Adeel Khan

Look, it's always about safety. Safety is always number one. Exosomes are so safe. And even mesenchymal stem cells have so much safety data around them, too. It's always about first do no harm. And this stuff does not have harm. And so why not try it as an alternative to opioids or to surgery for chronic pain, especially, right? Like it doesn't, to me, it baffles my mind, but it's very clear.

Look, it's always about safety. Safety is always number one. Exosomes are so safe. And even mesenchymal stem cells have so much safety data around them, too. It's always about first do no harm. And this stuff does not have harm. And so why not try it as an alternative to opioids or to surgery for chronic pain, especially, right? Like it doesn't, to me, it baffles my mind, but it's very clear.

Unfortunately, do you know what the most profitable drug now is?

Unfortunately, do you know what the most profitable drug now is?

No, it's actually methotrexate. It made something like $26 billion last year. So it surpassed spattens.

No, it's actually methotrexate. It made something like $26 billion last year. So it surpassed spattens.

It's an epidemic of autoimmune conditions, probably related to toxins in an environment, probably COVID, maybe everything else that's going on in the modern world. And so it's just an epidemic. And you and I both know you can treat many of these just through nutrition and lifestyle, but most doctors don't know anything about that. So of course they're just prescribing medications.

It's an epidemic of autoimmune conditions, probably related to toxins in an environment, probably COVID, maybe everything else that's going on in the modern world. And so it's just an epidemic. And you and I both know you can treat many of these just through nutrition and lifestyle, but most doctors don't know anything about that. So of course they're just prescribing medications.

And we know these things, wouldn't you rather be on something that's going to regulate your immune system and fix it than just suppress it, which may cause cancer, right? Like it doesn't, the risk benefit, it just makes no sense, you know? And I think you always have to look at what's called number needed to treat versus number needed to harm.

And we know these things, wouldn't you rather be on something that's going to regulate your immune system and fix it than just suppress it, which may cause cancer, right? Like it doesn't, the risk benefit, it just makes no sense, you know? And I think you always have to look at what's called number needed to treat versus number needed to harm.

And that's essentially just a fancy, fancy way of just saying benefit versus harm. And if you look at that for a lot of the pharmaceuticals, it's not that great. Um,

And that's essentially just a fancy, fancy way of just saying benefit versus harm. And if you look at that for a lot of the pharmaceuticals, it's not that great. Um,

Yeah, because to me, then you have these interventions that we're seeing that are reducing inflammation, oxidative stress, that are helping with so many different chronic diseases and they don't have harm. So why not have them as a first line as opposed to going straight to a lot of these pharmaceuticals that have risk? And that to me is kind of the logic.

Yeah, because to me, then you have these interventions that we're seeing that are reducing inflammation, oxidative stress, that are helping with so many different chronic diseases and they don't have harm. So why not have them as a first line as opposed to going straight to a lot of these pharmaceuticals that have risk? And that to me is kind of the logic.

And on your note of Muse exosomes, the reason they're... superior to standard exosomes is simply because they're from that new cell lineage.

And on your note of Muse exosomes, the reason they're... superior to standard exosomes is simply because they're from that new cell lineage.

So when new cells are replicating and when they're growing, the soup that they're growing in, that's what we're isolating, which has the signaling profile, meaning that secretome, which we talked about earlier, is superior than just a standard mesenchymal stem cell. So it has a better profile, number one.

So when new cells are replicating and when they're growing, the soup that they're growing in, that's what we're isolating, which has the signaling profile, meaning that secretome, which we talked about earlier, is superior than just a standard mesenchymal stem cell. So it has a better profile, number one.

And number two, because it is from a stressed, enduring lineage too, meaning the exosomes can stick around longer than standard exosomes, which it cleared up pretty quickly.

And number two, because it is from a stressed, enduring lineage too, meaning the exosomes can stick around longer than standard exosomes, which it cleared up pretty quickly.